Intervacc AB (publ) (FRA:2E9)

Market Cap	25.97M -16.4%
Revenue (ttm)	1.64M -0.7%
Net Income	-8.29M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24
Open	0.0547
Previous Close	0.0556
Day's Range	0.0547 - 0.0547
52-Week Range	0.0067 - 0.1004
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2E9

Financial Performance

In 2025, Intervacc AB's revenue was 20.09 million, an increase of 70.42% compared to the previous year's 11.79 million. Losses were -80.82 million, 7.02% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error